Why Baxter International Stock Skyrocketed by 19% This Week
Key Points
It scored double beats on analyst estimates.
It also lifted its guidance on both the top and bottom lines.
- 10 stocks we like better than Baxter International ›
Baxter International (NYSE: BAX) probably didn't want this trading week to end. According to data compiled by S&P Global Market Intelligence, the veteran medical device purveyor's shares flew 19% higher over the period. That was hardly a surprise, as the company published a highly encouraging quarterly earnings report Thursday morning.
There's nothing as good as a double beat
Baxter posted second-quarter sales of $2.96 billion, which was a 5% improvement over the same period of 2025. Of these, the company's take in its native U.S. rose 4% to $1.6 billion, while international sales advanced 7% to $1.4 billion.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Net income under generally accepted accounting practices (GAAP) rose more steeply, to $135 million from the year-ago profit of $122 million. On a per-share, non-GAAP (adjusted) basis, profitability fell 5% to $0.56 per share.
On average, analysts tracking Baxter stock were modeling $2.8 billion for revenue and $0.37 per share for adjusted net income.
In terms of product categories, both of Baxter's revenue buckets saw sales increases. Medical products and therapies posted a 7% gain to nearly $2.1 billion, while healthcare systems and technologies rose 4% to $801 million.
Popping on guidance
Those tailwinds inspired Baxter management to raise its full-year guidance. It's now anticipating sales growth of 3% to 4% over the 2025 tally. Previously, it was guiding for a flat-to-1% increase. Adjusted earnings per share (EPS) is projected to range from $1.95 to $2.15, up from the prior $1.85 to $2.05.
Baxter is solid, steady, and operating in a world where populations are getting proportionally older (and therefore requiring more medical care). It's well-positioned for continued growth, and with that, its stock is more than worthy of consideration as a buy.
Should you buy stock in Baxter International right now?
Before you buy stock in Baxter International, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Baxter International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $394,601!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,197,093!*
Now, it’s worth noting Stock Advisor’s total average return is 895% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 31, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
